The ADNI PET Core at 20

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2024 Aug 7

PMID 39108002

Authors

William J Jagust

Robert A Koeppe

Gil D Rabinovici

Victor L Villemagne

Theresa M Harrison

Susan M Landau

Affiliations

Soon will be listed here.

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) PET Core has evolved over time, beginning with positron emission tomography (PET) imaging of a subsample of participants with [F]fluorodeoxyglucose (FDG)-PET, adding tracers for measurement of β-amyloid, followed by tau tracers. This review examines the evolution of the ADNI PET Core, the novel aspects of PET imaging in each stage of ADNI, and gives an accounting of PET images available in the ADNI database. The ADNI PET Core has been and continues to be a rich resource that provides quantitative PET data and preprocessed PET images to the scientific community, allowing interrogation of both basic and clinically relevant questions. By standardizing methods across different PET scanners and multiple PET tracers, the Core has demonstrated the feasibility of large-scale, multi-center PET studies. Data managed and disseminated by the PET Core has been critical to defining pathophysiological models of Alzheimer's disease (AD) and helped to drive methods used in modern therapeutic trials. HIGHLIGHTS: The ADNI PET Core began with FDG-PET and now includes three amyloid and three tau PET ligands. The PET Core has standardized acquisition and analysis of multitracer PET images. The ADNI PET Core helped to develop methods that have facilitated clinical trials in AD.

Citing Articles

Explainable Artificial Intelligence in Neuroimaging of Alzheimer's Disease.

Taiyeb Khosroshahi M, Morsali S, Gharakhanlou S, Motamedi A, Hassanbaghlou S, Vahedi H Diagnostics (Basel). 2025; 15(5).

PMID: 40075859 PMC: 11899653. DOI: 10.3390/diagnostics15050612.

Targeting mitophagy in neurodegenerative diseases.

Antico O, Thompson P, Hertz N, Muqit M, Parton L Nat Rev Drug Discov. 2025; .

PMID: 39809929 DOI: 10.1038/s41573-024-01105-0.

Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification.

Landau S, Harrison T, Baker S, Boswell M, Lee J, Taggett J Alzheimers Dement. 2024; 21(1):e14378.

PMID: 39559932 PMC: 11772732. DOI: 10.1002/alz.14378.

The ADNI PET Core at 20.

Jagust W, Koeppe R, Rabinovici G, Villemagne V, Harrison T, Landau S Alzheimers Dement. 2024; 20(10):7340-7349.

PMID: 39108002 PMC: 11485322. DOI: 10.1002/alz.14165.

References

Sabri O, Sabbagh M, Seibyl J, Barthel H, Akatsu H, Ouchi Y . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015; 11(8):964-74. DOI: 10.1016/j.jalz.2015.02.004. View

Klunk W, Koeppe R, Price J, Benzinger T, Devous Sr M, Jagust W . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2014; 11(1):1-15.e1-4. PMC: 4300247. DOI: 10.1016/j.jalz.2014.07.003. View

Mormino E, Kluth J, Madison C, Rabinovici G, Baker S, Miller B . Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2008; 132(Pt 5):1310-23. PMC: 2677792. DOI: 10.1093/brain/awn320. View

Donohue M, Sperling R, Petersen R, Sun C, Weiner M, Aisen P . Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA. 2017; 317(22):2305-2316. PMC: 5736301. DOI: 10.1001/jama.2017.6669. View

Foster N, Chase T, Fedio P, Patronas N, Brooks R, DI CHIRO G . Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology. 1983; 33(8):961-5. DOI: 10.1212/wnl.33.8.961. View

Alexander G, Chen K, Pietrini P, Rapoport S, Reiman E . Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry. 2002; 159(5):738-45. DOI: 10.1176/appi.ajp.159.5.738. View

Joshi A, Koeppe R, Fessler J . Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009; 46(1):154-9. PMC: 4308413. DOI: 10.1016/j.neuroimage.2009.01.057. View

Small G, Ercoli L, Silverman D, Huang S, Komo S, Bookheimer S . Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000; 97(11):6037-42. PMC: 18554. DOI: 10.1073/pnas.090106797. View

Landau S, Ward T, Murphy A, Iaccarino L, Harrison T, La Joie R . Quantification of amyloid beta and tau PET without a structural MRI. Alzheimers Dement. 2022; 19(2):444-455. DOI: 10.1002/alz.12668. View

10.

Clark C, Pontecorvo M, Beach T, Bedell B, Coleman R, Doraiswamy P . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012; 11(8):669-78. DOI: 10.1016/S1474-4422(12)70142-4. View

11.

Landau S, Breault C, Joshi A, Pontecorvo M, Mathis C, Jagust W . Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2012; 54(1):70-7. PMC: 3747730. DOI: 10.2967/jnumed.112.109009. View

12.

Pfeffer R, Kurosaki T, Harrah Jr C, Chance J, Filos S . Measurement of functional activities in older adults in the community. J Gerontol. 1982; 37(3):323-9. DOI: 10.1093/geronj/37.3.323. View

13.

Chien D, Bahri S, Szardenings A, Walsh J, Mu F, Su M . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2012; 34(2):457-68. DOI: 10.3233/JAD-122059. View

14.

Baker S, Maass A, Jagust W . Considerations and code for partial volume correcting [F]-AV-1451 tau PET data. Data Brief. 2017; 15:648-657. PMC: 5671473. DOI: 10.1016/j.dib.2017.10.024. View

15.

Ewers M, Insel P, Jagust W, Shaw L, Trojanowski J, Aisen P . CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2011; 22(9):1993-2004. PMC: 3500862. DOI: 10.1093/cercor/bhr271. View

16.

Guo T, Korman D, Baker S, Landau S, Jagust W . Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. Biol Psychiatry. 2020; 89(8):786-794. PMC: 9682985. DOI: 10.1016/j.biopsych.2020.06.029. View

17.

Friedland R, Budinger T, Ganz E, Yano Y, Mathis C, Koss B . Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr. 1983; 7(4):590-8. DOI: 10.1097/00004728-198308000-00003. View

18.

Royse S, Minhas D, Lopresti B, Murphy A, Ward T, Koeppe R . Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021; 13(1):99. PMC: 8111744. DOI: 10.1186/s13195-021-00836-1. View

19.

Landau S, Mintun M, Joshi A, Koeppe R, Petersen R, Aisen P . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012; 72(4):578-86. PMC: 3786871. DOI: 10.1002/ana.23650. View

20.

Chen K, Langbaum J, Fleisher A, Ayutyanont N, Reschke C, Lee W . Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage. 2010; 51(2):654-64. PMC: 2856742. DOI: 10.1016/j.neuroimage.2010.02.064. View